- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02191423
Oxytocin and Dyadic Psychotherapy in the Treatment of Post Partum Depression
The Effect of Oxytocin on Brain Attachment and Empathy Networks, and the Association Between the Brain Response and Treatment Outcome of Brief Dyadic Psychotherapy - in Women Suffering From Postpartum Depression
Rationale and Hypotheses of the Current Research: the investigators speculate that mothers suffering from PPD exhibit high levels of depression and low levels of OXT, hence experiencing the interaction with their child as less rewarding, which in turn promote further depressive symptoms and interfere with child development. While dyadic psychotherapy has been studied in this context, it is unknown which depressed women will respond to this type of therapy, and whether such a response is mediated by the pro-bonding effect of oxytocin.
The aim of this study is three-fold:
- To study the effect of the administration of a single dose (24IU) of oxytocin on cerebral circuit processing and connectivity of empathy and attachment.
- To examine whether the clinical response of mothers suffering from postpartum depression to short term dyadic psychotherapy (based on improved mother-child interactions) can be predicted by a unique brain response pattern to oxytocin.
- To assess the relationship between levels of oxytocin in mother and baby and the effectiveness of psychological dyadic treatment on mothers suffering from postpartum depression.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Miki Bloch, Prof.
- Phone Number: 972-3-6974707
- Email: mikib@tlvmc.gov.il
Study Contact Backup
- Name: Ruth Feldman, PhD
- Phone Number: 972-3-5317943
- Email: ortalsh@hotmail.com
Study Locations
-
-
-
Tel-Aviv, Israel
- The Tel-Aviv Sourasky Medical Center
-
Principal Investigator:
- Miki Bloch, Prof.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Women of all ages who are 3 to 8 months post-partum.
- Women who have completed a minimum of 12 years of education.
- Women who are willing and able to provide informed consent for their participation and after the study has been explained. Infant participation will be allowed after consent has been obtained from mothers.
- Current DSM-IV-TR diagnosis of PPD disorder as confirmed by SCID (administered as part of the study of protocol number PPD1, proposed to the Helsinki committee on June 2014).
- Symptoms: BDI total score >9, EPDS total score >10
- Treatment with antidepressants will be allowed provided that patients have been on the medication for at least 4 weeks prior to entry into the pre-treatment assessment phase of the study.
Exclusion Criteria:
- Unwilling or unable, in the opinion of the investigator, to comply with study instructions.
- Pregnant women.
- Clinically significant medical disease (malignancy, poorly controlled diabetes, active ischemic cardiac disease, or cardiomyopathy, serious pulmonary disease, kidney disease, impaired liver functioning).
- Women with significant risk of committing suicide or harming others in the opinion of the psychiatrist.
- Women with a current DSM-IV-TR substance or alcohol abuse. However, patients with a history of and/or current recreational use of cannabinoids or alcohol, and/or patients who smoke cigarettes can be included.
- Women who suffers from depression due to physical condition.
- Women who suffers from severe major depression (MADRAS>30)
- Women who suffers from chronic depression (over 6 months)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: postpartum depression
Women suffering from postpartum depression, assessed by fMRI and then treated by dyadic psychotherapy
|
administered pre-fMRI assessment
Other Names:
administered pre-fMRI assessment
|
Other: normal controls
Normal control women not suffering from postpartum depression assessed by fMRI
|
administered pre-fMRI assessment
Other Names:
administered pre-fMRI assessment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effect of the administration of oxytocin on cerebral circuit processing
Time Frame: Two functional brain scans one week after admission to the study (week2)
|
1. This paradigm assesses empathic responses to images of individuals experiencing sad, anxious and happy events. Images are preceded by social context (i.e. "this person just won the lottery"). Control condition presents participants with images of people performing everyday actions. 3.we generated 15 short screenplays containing triggers for both types of empathy. Each of the screenplays depicts a situation in which the characters pose a negatively-valenced bodily state (e.g. crying, itching, choking), which we expect to elicit embodied simulation in the viewer. 2. This paradigm examines maternal FMRI responses to infant related video vignettes. Stimuli include movies of mothers' own infant vs strange infant during solitary play and mother-infant interaction. |
Two functional brain scans one week after admission to the study (week2)
|
Interactional measures-CIB
Time Frame: pre (baseline at week 1) and post (week 11) experimental trial assessments. Data will be presented up to 1 year
|
The Coding Interactive Behavior Manual (CIB) (Feldman 1998), a well-validated system for coding dyadic interactions, by individuals blind to the study group that the participant is a member in.
The following behaviors will be compute: Parents behavior; Child behavior; Dyadic behavior; Lead-Lag Relationship
|
pre (baseline at week 1) and post (week 11) experimental trial assessments. Data will be presented up to 1 year
|
Interactional measures-Noldus
Time Frame: pre (baseline at week 1) and post (week 11) experimental trial assessments. Data will be presented up to 1 year
|
Micro-analytic coding of synchrony- on a computerized system (Noldus, The Vaggenigen, Netherlands), coded on a computerized system that allows for .01-second
exactness.
Consistent with previous research on parent-infant synchrony (Feldman and Eidelman, 2004, 2007).
Four non-verbal categories of parenting behavior and four non-verbal categories of infant behavior will be coded and each category will include a set of mutually exclusive codes.
|
pre (baseline at week 1) and post (week 11) experimental trial assessments. Data will be presented up to 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maternal depression symptoms measures- BDI
Time Frame: mothers will complete the BDI once a week during the 8-week trial, as well as in the pre (baseline at week 1) and post (week 11) experimental trial assessments. Data will be presented up to 1 year
|
Beck Depression Inventory- BDI (Beck, Ward, Mendelson, Mock, and Erbaugh, 1961) is designed to assess the severity of depression while referring to affective, cognitive, physical and behavioral aspects. The BDI consists of 21 items, divided in to 3 factors: sadness / negative self perception, psycho-motor deceleration and somatic depression. Every item consists of 4 sentences for self-esteem, in a scale of 0-3, according to the degree of depression. Scores of 9 or above indicate elevated depressive symptoms and a risk for MDD (Kendall, Hollon, Beck, et al 1987). The BDI is a widely used inventory which was found to be well validated and highly coefficient (for a meta analysis see: Beck, Steer, & Garbin, 1988). |
mothers will complete the BDI once a week during the 8-week trial, as well as in the pre (baseline at week 1) and post (week 11) experimental trial assessments. Data will be presented up to 1 year
|
Maternal depression symptoms measures - EPDS
Time Frame: pre (baseline at week 1) and post (week 11) experimental trial assessments. Data will be presented up to 1 year
|
Edinburgh Postnatal Depression Scale- EPDS, (Cox, Holden, Sagovsky, 1987) is designed in order to screen for postnatal depression in the community.
The EPDS is a brief (10-item) scale.
The questions focus on the psychological rather than the somatic aspects of depression and explore 2 distinct domains of negative affect: depressive symptoms (7 items) and anxiety (3 items) (Kabir, Sheeder and Kelly, 2008).
Subjects respond to items on a 4 point Likert scale (of 0-3), resulting in a total score range between 0 and 30.
Scores of 10 or above indicate elevated depressive symptoms and a risk for PPD (Cox, Holden, Sagovsky, 1987).
The EPDS is a widely used scale which was found to be well validated and highly coefficient (Cox, Holden, Sagovsky, 1987; Kabir, Sheeder and Kelly ,2008; Murray & Carothers, 1990).
|
pre (baseline at week 1) and post (week 11) experimental trial assessments. Data will be presented up to 1 year
|
Maternal anxiety measures-STAI
Time Frame: mothers will complete the STAI once a week during the 8-week trial, as well as in the pre (baseline at week 1) and post (week 11) experimental trial assessments. Data will be presented up to 1 year
|
State- Trait Anxiety Inventory- STAI (Spielberger, Gorsuch, and Lushene, 1970) assesses levels of situational and trait anxiety.
The STAI contains 40 declarations, 20 of which refer to situational anxiety and 20 of which refer to trait anxiety.
Subjects will indicate on a scale of 1-4 (1=not it all, 4=to a large extent) to what extent they think the declaration is accurate in their case.
Trait anxiety scores of above 43 are considered a risk indicator for anxiety disorders (Spielberger, et al., 1970).
The STAI is a widely used inventory which was found to be well validated and highly coefficient (Anastasi, 1988).
|
mothers will complete the STAI once a week during the 8-week trial, as well as in the pre (baseline at week 1) and post (week 11) experimental trial assessments. Data will be presented up to 1 year
|
Physiological measures-Salivary OXT
Time Frame: both mothers and infants will give six saliva samples; once a other week during the 8-week trial, as well as in the pre (baseline at week 1) and post (week 11) experimental trial assessments. Data will be presented up to 1 year
|
Salivary OXT -in order to examine OXT and reactivity curve in PPD women and their infants
|
both mothers and infants will give six saliva samples; once a other week during the 8-week trial, as well as in the pre (baseline at week 1) and post (week 11) experimental trial assessments. Data will be presented up to 1 year
|
Maternal thought and action measures
Time Frame: mothers will complete the YIPTA twice; in the pre (baseline at week 1) and post (week 11) experimental trial assessments. Data will be presented up to 1 year
|
Maternal thoughts and actions will be assessed with the Yale Inventory of Parental Thoughts and Actions (YIPTA) - a semi-structured interview which provides a validated measure of parental worries, comprising a range of anxious intrusive thoughts and harm avoidant behaviors (AITHAR; Feldman, Weller, Leckman, Kuint, & Eidelman, 1999; Leckman et al., 2004; Leckman et al., 1999; Mayes, Swain, Feldman, & Leckman, 2008).
Such thoughts and behaviors include concerns about the baby's physical environment.
|
mothers will complete the YIPTA twice; in the pre (baseline at week 1) and post (week 11) experimental trial assessments. Data will be presented up to 1 year
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TASMC-14-MB-161-CTIL
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Postpartum Depression
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Women's Health Research Institute...CompletedPostpartum Depression | Perinatal Disorder | Postpartum Disorder | Perinatal Depression | Postpartum Anxiety | Postnatal DepressionCanada
-
University of CoimbraEnrolling by invitationPostPartum DepressionPortugal
-
University of MinnesotaNational Institute of Mental Health (NIMH)Completed
-
Sage TherapeuticsCompletedSevere Postpartum DepressionUnited States
-
Women's College HospitalCanadian Institutes of Health Research (CIHR); Michael Garron HospitalCompletedPostpartum Depression | Postpartum Anxiety | Postpartum Blues | Postpartum Mood DisorderCanada
-
Gazi UniversityCompletedPostpartum Depression | Postpartum AdaptationTurkey
-
British Columbia Children's HospitalActive, not recruiting
-
University of RochesterMae Stone Goode FoundationCompletedPostpartum Depression | Postpartum AnxietyUnited States
-
Hacettepe UniversityCompletedQuality of Life | Postpartum Depression | Nursing Caries | Nurse's Role | Postpartum Disorder | Postpartum AnxietyTurkey
Clinical Trials on Oxytocin
-
University of Electronic Science and Technology...Completed
-
Hillel Yaffe Medical CenterUnknownCervix; Insufficient Dilatation in LaborIsrael
-
University of NebraskaNational Institute of Mental Health (NIMH)Terminated
-
GlaxoSmithKlineCompletedPostpartum HemorrhageUnited Kingdom
-
University of Electronic Science and Technology...Recruiting
-
GlaxoSmithKlineMonash University; InVentiv CliniqueTerminatedPostpartum HemorrhageAustralia, United Kingdom
-
University Hospital, ToulouseCompleted
-
OptiNose ASUniversity of OsloCompletedHealthy Male AdultsNorway
-
Washington University School of MedicineUniversity of MichiganRecruiting
-
Wake Forest University Health SciencesNational Institute of Neurological Disorders and Stroke (NINDS)CompletedHealthy Volunteer StudyUnited States